Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS-8
- Development stage
- Preclinical
- Lead developer
- Resolute Science
- Modality
- Small Molecules
01
Overview
RS-8 is a preclinical-stage drug candidate developed by Resolute Science, Inc. It is part of their proprietary Macrophage-Targeted Conjugates (MAC-TACs) platform, which utilizes synthetic drug conjugates to target tumor-associated macrophages (TAMs) within solid tumors. The MAC-TAC technology aims to deliver cytotoxic or radiotherapeutic payloads to cancer cells by leveraging the natural biology of TAMs, which are abundant in solid tumors and consistently express a targeted receptor. This approach is designed to overcome resistance mechanisms often encountered with cancer-cell-targeting therapies and is being developed for pan-cancer solid tumor indications.
02
Targets
TAM (TAM receptor tyrosine kinases)
Beyond the preview
Go deeper on RS-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS-8.